

25<sup>th</sup> May, 2022

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Presentation to analysts on Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2022**

The presentation on Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2022 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

Encl : A/a



## Q4 FY 2021-22

Revenue: Summary



## Revenue: Summary

Revenue (Rs cr)	Q4 FY22	Q4 FY21	Gr%
India	1,034	922	12%
United States	282	269	5%
Germany	218	267	-18%
Brazil	251	189	33%
Other countries	218	195	12%
Others	129	95	35%
<b>Total</b>	<b>2,131</b>	<b>1,937</b>	<b>10%</b>

